Cost Savings
Projected outcomes using a digital service model for COPD
Annual costs were projected to decrease by £3.38 million with a reduction in healthcare resource utilisation associated with occupied bed days for 500 users
Savings matrix
Projections across service user numbers and bed day costs
| £800/obd | £1,000/obd | £1,200/obd | £1,492/obd | |
|---|---|---|---|---|
| 200 users | £724,800 | £906,000 | £1,087,200 | £1,351,988 |
| 300 users | £1,087,200 | £1,359,000 | £1,630,800 | £2,027,981 |
| 400 users | £1,449,600 | £1,812,000 | £2,174,400 | £2,703,975 |
| 500 users | £1,812,000 | £2,265,000 | £2,718,000 | £3,379,969 |
| 600 users | £2,174,400 | £2,718,000 | £3,261,600 | £4,055,963 |
Evidence stats
How the Lenus Service can reduce costs associated with healthcare resource utilisation
-
4.53
Fewer OBD per patient per year
-
£1,492
Estimated cost per OBD in Scotland
Table supplement
More information on the data presented
- Cost per occupied bed day in 2017/18 period was £1,190, a 25.4% increase on the 2013/14 period (information services division, NHS Scotland).
- Applying this same increase, the cost per occupied bed day is taken to be £1,492.26 in 2022.
Study details
ClinicalTrials.gov Identifier: NCT04240353
The feasibility and service adoption observational cohort RECEIVER trial was commenced in September 2019 by NHS Greater Glasgow and Clyde to evaluate the implementation and efficacy of the Lenus COPD Service with high-risk COPD participants matched 1:5 to a control cohort using de-identified contemporary routine clinical data. In March 2021, 'RECEIVER' recruitment was paused and a 'Dynamic-Scot' cohort was established through remote recruitment in the Covid-19 service scale-up to routine care. The protocol is published here with the full results available here.
| Control | RECEIVER | Dynamic-Scot 1 | Service users | |
|---|---|---|---|---|
| Inclusion Criteria |
Selected from the NHS Greater Glasgow and Clyde SafeHaven dataset. Diagnosis of COPD + a COPD-related hospital admission within a 14-day window of a reference RECEIVER trial participant's onboarding date were criteria for entry. From these criteria, the optimal ~5 matches for each RECEIVER participant were determined based on sex and age whilst excluding duplicate control patients or individuals subsequently onboarded to Lenus COPD. |
At least one severe COPD exacerbation in the year prior to onboarding to Lenus COPD and/or chronic hypercapnic respiratory failure/sleep disordered breathing requiring NIV/CPAP treatment. | Onboarded at least 365 days before 31/08/2021 (the data censor date for analyses). | RECEIVER and Dynamic-Scot 1 participants. |
| 1st Participant Index Date | 3rd September 2019 | 3rd September 2019 | 15th May 2020 | 3rd September 2019 |
| Censor Date | 31st August 2021 | |||
| Total Patients | 405 | 83 | 142 | 225 |
NICE advice
Medtech Innovation Briefing
The National Institute of Health and Care Excellence (NICE) has developed a medtech innovation briefing (MIB) on Lenus COPD Support Service for remotely managing chronic obstructive pulmonary disease available here.
Get in touch
Got a service in mind for Lenus? Talk to us today.